Matthew Deangelis

Matthew DeAngelis currently serves as the Associate Director of Clinical Operations in Cell Therapy (CAR-T) at Immix Biopharma, a role assumed in April 2024. Prior to this, Matthew held the position of Associate Director of Clinical Operations at Cabaletta Bio from December 2021 to April 2024, where responsibilities included leading the phase 1 clinical program for MuSK-CAART targeting autoimmune diseases. Matthew's experience also includes significant roles at Seven and Eight Biopharmaceuticals Inc., Merck, and Vifor Pharma, with a focus on clinical development across various therapeutic areas including Anesthesia, Critical Care, and autoimmune conditions. Matthew's educational background includes a Bachelor of Arts in Psychology from Rutgers University.